Boston-based Beth Israel Deaconess Medical Center researchers have found GLP-1 drugs were associated with fewer peptic ulcer diagnoses among patients with Type 2 diabetes.
The study, published in Clinical Gastroenterology and Hepatology, analyzed EHR data from more than 66,000 adults enrolled in the National Institutes of Health’s All of Us Research Program, according to an April 29 hospital news release. Patients using GLP-1 medications had 44% lower odds of being diagnosed with peptic ulcer disease compared to nonusers.
In a subgroup analysis, patients who stopped taking metformin and initiated a GLP-1 drug had a 56% lower risk of developing peptic ulcer disease than those who switched to insulin.
Peptic ulcer disease affects an estimated 4 million people each year and remains a cause of hospitalization, particularly among patients with Type 2 diabetes. Researchers said the findings suggest GLP-1 receptor agonists may have broader gastrointestinal effects, including anti-inflammatory properties and potential roles in mucosal protection.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
